I. Why Shaanxi's Pharmaceutical Manufacturing Merits Attention
Shaanxi's pharmaceutical manufacturing industry ranks among the stronger performers in central and western China, yet tends to be underestimated by outside observers. The reason is partly structural: the province is best known for energy, chemicals, and historical tourism, while pharmaceuticals have accumulated considerable scale in relative silence.
In 2024, the 286 above-scale enterprises in Shaanxi's pharmaceutical and medical device industry chain recorded a combined industrial output of RMB 50.8 billion (source: Shaanxi Provincial Department of Industry and Information Technology). That same year, the Shaanxi Provincial Development and Reform Commission published an action plan targeting RMB 120 billion in pharmaceutical cluster output by 2030. A government target of this magnitude is not conceived in a vacuum — it reflects a sector with genuine existing foundations.
Historically, Shaanxi's pharmaceutical industry rests on two pillars. The first is natural endowment: the Qinling Mountains and surrounding regions support an unusually rich reservoir of genuine-origin (daodi) Chinese medicinal materials. The second is industrial history: Xi'an, as the central city of northwest China, attracted Xi'an Janssen Pharmaceutical — a joint venture with Johnson & Johnson — as early as 1985, establishing an early precedent for international pharmaceutical cooperation in the region.
II. Geographic Clusters: Xi'an–Xianyang as the Core, Multiple Peripheral Nodes
The geographic logic of Shaanxi's pharmaceutical industry can be summarized as one center with several support nodes.
The core is the Xi'an–Xianyang metropolitan area. Xi'an High-Tech Zone hosts Xi'an Janssen Pharmaceutical, Xi'an Libang Pharmaceutical, Shaanxi Tianyu Pharmaceutical, Xi'an Lijun Pharmaceutical, and others, concentrated primarily in chemical drugs and biologics. As of February 2023, Xi'an accounted for 51 of Shaanxi's chemical drug R&D and manufacturing enterprises, and 485 of its medical device enterprises — both provincial highs (source: Zhihu analysis citing Shaanxi Drug Administration data). Xianyang focuses on modern traditional Chinese medicine (TCM), hosting Shaanxi Buchang Pharmaceutical, Shaanxi Dongtai Pharmaceutical, and Shaanxi Bailu Pharmaceutical, with the Xianyang modern TCM industrial cluster generating approximately RMB 40 billion in annual output.
Hanzhong, to the south, serves as a major TCM finished-product production base. Shaanxi Hanjiang Pharmaceutical Group operates its core manufacturing here; Xiuzheng Pharmaceutical Group's Tianhan Pharmaceutical plant is also located in this area. Ankang and Shangluo, rich in medicinal plant resources, host smaller TCM manufacturers positioned close to their raw material supply.
III. Leading Enterprises
Shaanxi Pharmaceutical Group (陕药集团) is the province's largest state-owned pharmaceutical enterprise, spanning both distribution and manufacturing. Its manufacturing subsidiaries include Shanhaidan Pharmaceutical and Shaanxi Dongtai Pharmaceutical. The group reported RMB 26.9 billion in revenue in 2022, operated 20 provincial-level engineering technology centers, and maintained product lines covering chemical drugs, TCM finished products, and medical devices (source: Shaanxi Pharmaceutical Group official website and public disclosures).
Panlong Pharmaceutical (陕西盘龙药业集团股份有限公司, SZSE: 002864) is one of Shaanxi's few A-share-listed TCM manufacturers. Its flagship product, Panlong Qipian, is a proprietary patented compound for orthopedic and rheumatic conditions, classified as a Category A item under the national medical insurance formulary, with a gross margin consistently above 85%. The 2023 annual report shows that TCM finished-product revenue accounted for more than 57% of total sales, with the company also operating TCM decoction pieces and pharmaceutical distribution businesses (source: Panlong Pharmaceutical 2023 Annual Report, disclosed April 2024).
Buchang Pharmaceutical's Shaanxi operations — Buchang Group's Shaanxi subsidiary (Shaanxi Buchang Pharmaceutical) was named a 2024 Shaanxi Province Outstanding Unit in Industrial and Information Technology Work (source: Arterial Network). The parent group (Buchang Pharmaceutical, SSE: 603858) reported RMB 13.25 billion in consolidated revenue in 2023, a year-on-year decline of 11.4%, with cardiovascular and cerebrovascular TCM remaining the dominant income source; the Shaanxi facility contributes a portion of the group's production capacity.
Xi'an Janssen Pharmaceutical is one of the earliest multinational pharmaceutical joint ventures in China. Established in Xi'an High-Tech Zone in 1985, its factory was the first in China to meet international GMP standards. The company's portfolio spans gastroenterology, psychiatry, anti-infectives, and oncology, and its Xi'an workforce exceeds 3,000. Following Johnson & Johnson's global business restructuring, the Xi'an Janssen brand has been absorbed into the broader J&J China organization, but the Xi'an manufacturing site continues to operate and remains one of the few multinational drug production nodes in northwest China.
Other mid-tier enterprises — including Xi'an Lijun Pharmaceutical, Shaanxi Hanjiang Pharmaceutical, Shaanxi Xiangju Pharmaceutical, and Shaanxi Hanwang Pharmaceutical — fill out the next tier of the province's pharmaceutical industrial base.
IV. Upstream: The Qin Medicine Raw Material Base
The competitiveness of TCM manufacturing is substantially anchored in access to genuine-origin medicinal materials. Shaanxi holds a real advantage in this dimension.
The official "Ten Great Qin Medicines" brand covers varieties including Shangluo salvia (丹参), Hanzhong gastrodia (天麻), Baoji bupleurum (柴胡), Yangxian Chinese goldenseal (延胡索), and Lueyang eucommia (杜仲), among others. According to the Fourth National TCM Resource Survey, Shaanxi has 3,291 types of TCM resources, with 283 key varieties accounting for 77.7% of the national total of key varieties (source: CNR, "Shaanxi: Building the 'Qin Medicine' Brand from the Source," December 2023).
Key cultivation areas include: forsythia (连翘) at approximately 413,000 mu, astragalus (黄芪) at 156,500 mu, cornelian cherry (山茱萸) at 101,300 mu, scutellaria (黄芩) at 99,500 mu, and salvia (丹参) at 67,000 mu. Shangluo, Hanzhong, and Ankang are the three primary growing regions, collectively hosting thousands of cultivation bases that supply raw materials to TCM factories across the province. Eight varieties — including salvia, gastrodia, and jiaogulan — have received national GAP (Good Agricultural Practice) certification, providing a traceability foundation for downstream quality management.
V. Downstream: From Manufacturing to Distribution
A structural gap exists in Shaanxi's pharmaceutical value chain: manufacturing output is substantial, but provincial enterprises' penetration of national markets lags behind coastal counterparts in Jiangsu, Guangdong, and Shandong.
Within the province, Shaanxi Pharmaceutical Group's distribution arm is the dominant pharmaceutical logistics operator, handling supply to public hospitals and primary care institutions. For mid-tier manufacturers like Panlong Pharmaceutical and Xiangju Pharmaceutical, national market expansion relies more on third-party distributors or internal academic promotion teams. Buchang Pharmaceutical, with its nationally established cardiovascular TCM promotion network, provides its Shaanxi facility with access to a broader sales infrastructure.
On R&D integration, Xi'an Jiaotong University, Northwest University, and Shaanxi University of Chinese Medicine have formed research collaboration frameworks with local pharmaceutical enterprises. Some companies have established new drug pipelines through these partnerships, particularly in biologics and high-value TCM. However, the translation pathway from academic research to commercial production remains slow relative to more developed pharmaceutical hubs.
VI. Challenges and Transition
Shaanxi's pharmaceutical manufacturers face challenges that mirror national industry trends while reflecting specific local structural constraints.
Centralized procurement pressure is the most immediate force. Products like Panlong Qipian, Buchang's cardiovascular TCM, and generic chemical drugs from provincial manufacturers have all experienced price compression under national procurement policies. Panlong Pharmaceutical's pivot toward TCM decoction pieces and granule products is a typical diversification response, but this trajectory takes time to deliver material results.
Relatively limited R&D capacity is a second constraint. Only a small number of Shaanxi pharmaceutical enterprises invest more than RMB 100 million annually in R&D, and provincial manufacturing is still weighted toward mature TCM and generic drugs rather than innovative compounds. The Thousand-Billion Cluster Action Plan designates biologics and advanced chemical drugs as priority areas, but the existing industrial base requires sustained investment over several years before those targets become attainable.
Finally, brand recognition for Shaanxi pharmaceutical enterprises nationally remains weaker than that of counterparts in larger pharmaceutical provinces. Converting "Qin medicine" from a government-promoted concept into a market-recognized identity is a task that remains in its early stages.
Sales teams supplying raw materials, consumables, or equipment to pharmaceutical manufacturers in Shaanxi can use Tianxia Gongchang to filter factory directories and key contact information by province and pharmaceutical manufacturing sector.
VII. Summary
Shaanxi's pharmaceutical manufacturing sector is defined by three numbers: RMB 50.8 billion in above-scale industrial output, 286 above-scale enterprises, and 77.7% coverage of nationally key medicinal plant species. Together, they profile an inland pharmaceutical province that operates quietly but with a solid foundation. The Qin medicine resource base is Shaanxi's least-replicable asset; whether the province can translate this natural advantage into genuine manufacturing differentiation is the most consequential variable to watch in the years ahead.
Data Sources
- Tianxia Gongchang ( (Shaanxi pharmaceutical manufacturing factory directory and industry data)
- Shaanxi Provincial Department of Industry and Information Technology, "Shaanxi Intensifies Efforts to Cultivate a Hundred-Billion Pharmaceutical and Medical Device Innovation Cluster" (December 2024)
- Shaanxi Provincial Development and Reform Commission, "Action Plan for Cultivating a Hundred-Billion Pharmaceutical and Medical Device Innovation Cluster in Shaanxi" (October 2024)
- Panlong Pharmaceutical Group Co., Ltd. 2023 Annual Report (disclosed April 2024, Shenzhen Stock Exchange)
- CNR (China National Radio), "Shaanxi: Building the 'Qin Medicine' Brand from the Source" (December 2023)
- Zhihu, "Overview of Shaanxi's Biopharmaceutical Industry Landscape by City" (citing Shaanxi Drug Administration data)
- Shaanxi Pharmaceutical Group official website and public disclosures
- Arterial Network, "Buchang Pharmaceutical: Subsidiary Named 2024 Shaanxi Outstanding Unit in Industry and IT Work"